Journal Mobile Options
Table of Contents
Vol. 11, No. 4, 2000
Issue release date: July–August 2000
Dement Geriatr Cogn Disord 2000;11:230–237

A 26-Week Analysis of a Double-Blind, Placebo-Controlled Trial of the Ginkgo biloba Extract EGb 761® in Dementia

Le Bars P.L. · Kieser M. · Itil K.Z.
aMemory Centers of America Inc., bHZI Research Center, NeuroCorp Ltd, Elmsford, New York, N.Y., USA, and cDr. Willmar Schwabe Pharmaceuticals, Karlsruhe, Germany

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


This intent-to-treat (ITT) analysis was performed to provide a realistic image of the efficacy that could be expected after 26 weeks treatment with a 120-mg dose (40 mg t.i.d.) of EGb 761® (EGb). The data were collected during a 52-week, double-blind, placebo-controlled, fixed dose, parallel-group, multicenter study. Patients were mildly to severely impaired and diagnosed with uncomplicated Alzheimer’s disease or multi-infarct dementia according to ICD-10 and DSM-III-R criteria. The primary outcome measures included the Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS-Cog), Geriatric Evaluation by Relative’s Rating Instrument (GERRI) and Clinical Global Impression of Change. From 309 patients included in the ITT analysis, 244 patients (76% for placebo and 73% for EGb) actually reached the 26th week visit. In comparison to the baseline values, the placebo group showed a statistically significant worsening in all domains of assessment, while the group receiving EGb was considered slightly improved on the cognitive assessment and the daily living and social behavior. Mean treatment differences favored EGb with 1.3 and 0.12 points, respectively, on the ADAS-Cog (p = 0.04) and the GERRI (p = 0.007). In the group receiving EGb, 26% of the patients achieved at least a 4-point improvement on the ADAS-Cog, compared to 17% with placebo (p = 0.04). On the GERRI, 30% of the EGb group improved and 17% worsened, while the placebo group showed an opposite trend with 37% of patients worsening for 25% improved (p = 0.006). Regarding safety, no differences between EGb and placebo were observed.

Copyright © 2000 S. Karger AG, Basel

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Leber P: Observations and suggestions on antidementia drug development. Alzheimer Dis Assoc Disord 1996;10(suppl 1):31–35.
  2. Whitehouse PJ, Kittner B, Roessner M, Rossor M, Sano M, Thal L, Winblad B: Clinical trial designs for demonstrating disease-course-altering effects in dementia. Alzheimer Dis Assoc Disord 1998;12:281–294.
  3. Kanowski S, Herrmann WM, Stephan K, Wierich W, Hörr R: Proof of efficacy of the Ginkgo biloba special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia. Pharmacopsychiatry 1996;29:47–56.

    External Resources

  4. Le Bars PL, Katz MM, Berman N, Itil TM, Freedman AM, Schatzberg AF: A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. JAMA 1997;278:1327–1332.
  5. Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI: A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer’s disease. JAMA 1994;271:985–991.
  6. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT: A 24-week, double blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Neurology 1998;50:136–145.
  7. Kleijnen J, Knipschild P: Ginkgo biloba for cerebral insufficiency. Br J Clin Pharmacol 1992;34:352–358.
  8. Letzel H, Haan J, Feil WB: Nootropics: Efficacy and tolerability of products from three active substance classes. J Drug Dev Clin Pract 1996;8:77–94.
  9. DeFeudis FV (ed): Ginkgo biloba Extract (EGb 761): From Chemistry to the Clinic. Wiesbaden, Ullstein Medical, 1998.
  10. Rosen WG, Mohs RC, Davis KL: A new rating scale for Alzheimer’s disease. Am J Psychiatry 1984;141:1356–1364.
  11. Schwartz GE: Development and validation of the Geriatric Evaluation by Relative’s Rating Instrument (GERRI). Psychol Rep 1983;53:479–488.

    External Resources

  12. Clinical Global Assessment Scale (CGI); in Guy W (ed): ECDEU Assessment Manual for Psychopharmacology. Rockville, US Department of Health Education and Welfare, National Institute of Mental Health, 1976, pp 218–222.
  13. Gillings D, Koch G: The application of the principle of intention-to-treat to the analysis of clinical trials. Drug Inf J 1991;25:411–424.
  14. Kramer-Ginsberg E, Mohs RC, Aryan M, et al: Clinical predictors of course for Alzheimer patients in a longitudinal study: A preliminary report. Psychopharmacol Bull 1988;24:458–462.
  15. Stern RG, Mohs RC, Davidson M, Schmeidler J, Silverman J, Kramer-Ginsberg E, Searcey T, Bierer L, Davis KL: A longitudinal study of Alzheimer’s disease: Measurement, rate, and predictors of cognitive deterioration. Am J Psychiatry 1994;151:390–396.
  16. Agresti A: Tutorial on modeling ordered categorical response data. Psychol Bull 1989;105:290–301.
  17. Rother M, Erkinjuntti T, Roessner M, Kittner B, Marcusson J, Karlsson I: Propentofylline in the treatment of Alzheimer’s disease and vascular dementia: A review of phase III trials. Dement Geriatr Cogn Disord 1998;9(suppl 1):36–43.
  18. Chui H, Victoroff JI, Margolin D, Jagust W, Shankle R, Katzman R: Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer Disease Diagnostic and Treatment Centers (ADDTC). Neurology 1992;42:473–480.
  19. Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, et al: Vascular dementia: Diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993;43:250–260.
  20. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR: Brain infarction and the clinical expression of Alzheimer disease. JAMA 1997;277:813–817.
  21. Wallin A: The overlap between Alzheimer’s disease and vascular dementia: The role of white matter changes. Dement Geriatr Cogn Disord 1998;9(suppl 1):30–35.
  22. Morich FJ, Bieber F, Lewis JM, Kaiser L, Cutler NR, Escobar JI, Willmer J, Petersen RC, Reisberg B: Nimodipine in the treatment of probable Alzheimer’s disease. Results of two multicenter trials. Clin Drug Invest 1996;11:185–195.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50